natgillin/translations-raw huggingface dataset:
The use according to any one of claims 18 to 30, wherein the pharmaceutical composition further comprises an antioxidant/free radical scavenger agent, preferably nicaraven, ranolazine, emoxipin, glutatione, edaravone, raxofelast, lycopene, N-acetyl-L-cysteine, N-acetyl-D-cysteine, a racemic mixture of N-acetyl-L-cysteine and N-acetyl-D-cysteine, or carvedilol. 
Upotreba prema bilo kojem zahtjevu 18 do 30, naznačena time, da farmaceutski sastav nadalje sadrži antioksidant/sredstvo za hvatanje slobodnih radikala, ponajprije nikaraven, ranolazin, emoksipin, glutation, cdaravon, raksofclast, likopen, N-accetil-1-cistcin, N-acctil-D-cistcin, racemičnu smjesu N-acctil-1-cisteina i N- acetil-D-cisteina ili karvedilol.
contacting the antigen presenting cells of step (iii) with a T-cell to evaluate the ability of the peptide to stimulate the T-cells; and 
stavljanja u kontakt predočnih stanica iz koraka (iii) s T-stanicom kako bi se procijenilo sposobnost peptida da stimulira T-stanice; i
deducing the presence or absence of methylation of the CpG dinucleotides amplified in step b) from the results of step b). 
dedukciju prisutnosti ili odsutnosti metilacije CpG dinukleotida amplificiranih u koraku b) iz rezulata koraka b).
—O—C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, 
(4) Crsalkil, koji je nesupstituiran ili supstituiran sa halogenom, hidroksil ili fenil ili naftil,
a binding molecule comprising a heavy chain CDR1 region of SEQ ID NO:310, a heavy chain CDR2 region of SEQ ID NO:311, and a heavy chain CDR3 region of SEQ ID NO:312. The binding molecule of claim 1 wherein the binding molecule is able to recognize and bind to an epitope in the HA2 subunit of the influenza hemagglutinin protein (HA), wherein the binding molecule has neutralizing activity against an influenza virus comprising HA of the H5 subtype, and wherein the H5 subtype is selected from the group consisting of H5N1, H5N2, H5N8 and H5N9. 
Izolirano ljudsko antitijelo, ili njegov dio koji veže antigen, koje je sposobno za prepoznavanje i vezanje na epitop u podjedinici HA2 hemaglutinin proteina influence (HA), naznačeni time da navedeno antitijelo ili njegov dio koji veže antigen ima neutralizirajuću aktivnost protiv virusa influence koji sadrži HA podvrste H5, kao što su H5N1, H5N2, H5N8, i H5N9, te time da antitijelo ili njegov dio koji veže antigen sadrži varijabilno područje teškog lanca koje sadrži aminokiseline 1-121 iz SEQ ID NO: 65, i varijabilno područje lakog lanca koje sadrži aminokiseline 1-112 iz SEQ ID NO: 91.
Method according to claim 4, characterised in that the loop regions of Igk-C or Igl-C of human origin comprise at least one modification within amino acids 8 to 18, amino acids 27 to 35, amino acids 42 to 78, amino acids 83 to 85, amino acids 92 to 100, amino acids 108 to 117 or amino acids 123 to 126, where the numbering of the amino acid position of the domains is that of the IMGT. 
Postupak u skladu sa zahtjevom 19 ili 20, naznačen time, da imunoglobulin obuhvaća neko od područja petlje Igkapa ili Ig-lambda koja obuhvaćaju modifikaciju u jednom aminokiselinskom položaju unutar aminokiselinske sekvence izabrane iz skupine koju čine aminokiseline 8 do 20, aminokiseline 26 do 36, aminokiseline 43 do 79, aminokiseline 83 do 85, aminokiseline 90 do 101, aminokiseline 108 do 116 i aminokiseline 122 do 125, pri čemu je numeriranje prema IMGT.
Determination of the Degree of Pain / Discomfort. 
Datum podnošenja europske prijave patenta:
The method for preparing a nutritional composition for infant or child as a powder according to claim 7, characterized in that the at least two pectins of different natures correspond to at least one weakly methylated pectin, in particular an amidated and weakly methylated pectin, the degree of methylation of which is between 20% and 50%, and to at least one highly methylated pectin the degree of methylation of which is between 50% and 90%. 
Postupak priprave prehrambenog pripravka namijenjenog dojenčadi ili djeci u obliku praha u skladu s patentnim zahtjevom 8, naznačen time što najmanje dva pektina različite prirode odgovaraju najmanje jednom slabo metiliranom pektinu i najmanje jednom visoko metiliranom pektinu.
A nucleic acid comprising a nucleotide sequence encoding a human RNase 1 operatively linked with or without a linker to the N-terminus of a mutant human IgG1 Fc domain, and human DNase I operatively linked with or without a linker to the C-terminus of the mutant Fc domain, wherein the human RNase 1 comprises a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 149, with or without a leader sequence, and wherein the human DNase I comprises a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 139. The nucleic acid of claim 74, wherein the human RNase 1 comprises a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 149, without a leader sequence. The nucleic acid of claim 75, wherein the mutant Fc domain comprises a nucleotide sequence encoding one or more of the mutations selected from P238S, P331S, K322S, and N297S, numbering is according to the EU index. 
(b) pri čemu DNaza sadrži ljudsku DNazu, proizvoljno DNazu 1, proizvoljno sadrži sekvencu aminokiseline prikazanu u SEQ ID NO: 139, SEQ ID NO:143, ili SEQ ID NO:142 ili sadrži sekvencu aminokiseline koja je barem 90% identična sekvenci aminokiseline prikazanoj u SEQ ID NO: 139, SEQ ID NO:143, ili SEQ ID NO: 142; i/ili (c) Fc domena sadrži sekvencu aminokiseline koja je barem 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, ili 98% identična sekvenci aminokiseline prikazanoj u SEQ ID NO:145, proizvoljno sadrži modificiranu zglobnu domenu koja sadrži barem jednu supstituciju, proizvoljno pri čemu modificirana zglobna domena sadrži mutaciju u jednom ili više od tri cisteina, kao što su SCC ili SSS; i/ili proizvoljno sadrži jednu ili više Fc mutacija odabranih od P238S, P331S, K3228, i N297S.
upright rails guiding the panels stacked on top of each other; 
uspravne tračnice (3) za vođenje ploča (2) naslaganih jedna na drugu;
The rodent of claim 6, wherein the rodent comprises a replacement of a genomic fragment of a rodent IL-4Ra gene at an endogenous rodent IL-4Ra locus with a genomic fragment of a human IL4-Ra gene to form a humanized IL-4Ra gene that encodes said humanized IL-4Ra protein, wherein the genomic fragment of the rodent IL-4Ra gene comprises the ATG initiation codon of coding exon 1 through coding exon 5 of the rodent IL-4Ra gene, and the genomic fragment of the human IL-4Ra gene comprises the ATG initiation codon of coding exon 1 through coding exon 5 of the human IL-4Ra gene; wherein said humanized IL-4Ra gene comprises the ATG initiation codon of coding exon 1 through coding exon 5 of the human IL-4Ra gene, and coding exons 6-9 of the rodent IL-4Ra gene; and wherein expression of the humanized IL-4Ra gene is under control of rodent IL-4Ra regulatory elements at the endogenous rodent IL-4Ra locus. 
Glodavac u skladu s bilo kojim od patentnih zahtjeva 1-2, 4 1 6, naznačen time što je miš. Postupak dobivanja humaniziranog glodavca, naznačen time što se sastoji u zamjeni genomskog fragmenta gena za glodavački IL-4Ra na lokusu za endogeni glodavački IL-4Ra. genomskim fragmentom gena za ljudski IL-4Ra kako bi se dobilo gen za humanizirani IL-4Ra. koji sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ro, te kodirajuće egzone 6-9 gena za glodavački IL-4Ra, gdje genomski fragment gena za glodavački IL-4Ra. sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za glodavački IL-4Ra, a genomski fragment gena za ljudski IL-4Ra sadrži početni gen ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ra, gdje je gen za humanizirani IL-4Ro. operativno povezan s regulacijskim elementim glodavačkog IL-4Ra na lokusu za endogeni glodavački IL-4Ra.
contacting the compound of formula VI with an acid under conditions suitable for forming an acid solvate of a compound of formula II: 
H ožisa R3 OR* VI s kiselinom pod uvjetima pogodnim za tvorbu kiselog solvata spoja s formulom II:
and R5 are independently hydrogen or methyl. 
R* i R* su neovisno vodik ili metil.
The main fuel composition and the secondary fuel component may be pumped into separate storage tanks associated with the compression ignition engine. 
- sekundarnu komponentu goriva koja sadrži pojačivač paljenja, kao potpunu zamenu za tradicionalno dizelskog goriva za upravljanje motorom s kompresijskim paljenjem.
The fiber optic enclosure assembly as claimed in claim 8, wherein the second cables (126) can be optically connected to the first cable (22, 122). 
Postupak izvlačenja optičkog kabela odmotavanjem (22, 122) iz kutije sa optičkim kabelom prema Zahtjevu 1, gdje je kućište (23, 123) postavljeno na zid.
whereby a breath induced low pressure at the distal end of the airflow adaptor causes air to flow into the swirl chamber through the dry powder supply port and the inlet port. 
Postupak za podešavanje protoka zraka kroz izlaz deaglomeratora inhalatora suhog praha koji se aktivira disanjem, a koji obuhvaća korake:
The peptide-derived molecule according to claim 8 or the pharmaceutical composition according to claim 8 for use against (i) breast or prostate cancer and/or (ii) another cancer expressing androgen receptors alone or together with estradiol receptors. 
Molekula izvedena iz peptida prema zahtjevu 10 ili farmaceutski pripravak prema zahtjevu 10 naznačen time da je za upotrebu protiv (i) raka dojke ili prostate i/ili (1) drugih karcinoma koji eksprimiraju receptore za androgen zasebno ili zajedno s receptorima za estradiol.
is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; 
R;2 je izabran od vodika, alkila, cikloalkila, arila, heteroarila i heterociklila;
or a pharmaceutically acceptable salt thereof; (c) reacting Compound (F) or a pharmaceutically acceptable salt thereof with Compound (G): 
(c) reakciji Spoja (F), ili njegove farmaceutski prihvatljive soli, sa Spojem (G) X2 a.
The filter assembly for the fluid filter as claimed in claim 2, wherein the connecting pipe 12 of the connecting member 10 of a first one of the filter units is disposed in an output pipe 911 of a filter cover. 
Sklop filtera prema zahtjevu 1, naznačen time što je spojna cijev 12 spojnog elementa 10 prve od filterskih jedinica smještena u izlaznoj cijevi 911 poklopca filtera.
The coating composition according to claim 1, wherein the hydrophilic-modified polysiloxane has a number average molecular weight (Mn) in the range of 500-50,000 g/mol. 
Smjesa za premaz prema jednom od prethodno navedenih patentnih zahtjeva, naznačena time da hidrofilno modificirani polisiloksan ima prosječnu brojčanu molekulsku masu (M,) u rasponu od 500-50.000 g/mol.
An indolizine derivative as claimed in claim 8 or 9, wherein R1a represents a hydroxy group, or a prodrug thereof, or a pharmaceutically acceptable salt thereof. 
Derivat indolizina prema zahtjevu 8, gdje R1a predstavlja hidroksi skupinu, ili prolijek, ili farmaceutski prihvatljiva sol.
An alternative process, provided for reference purposes, relates to a large-scale process for preparing an alpha-aminoboronic ester compound of formula (VIIa) or (VIIb): or an acid addition salt thereof, wherein: 
PZ-N H 48. Postupak koji koristi najmanje pet mola najmanje jednog početnog materijala za pripremu spoja ostera aminoorganoborne kiseline formule (VIIa) ili (VIIb):
the first fragment comprises a first proximal end within a first repeat portion; 
(ili) prvi fragment sadrži prvi proksimalni kraj unutar prvog ponavljanog dijela;
A composition comprising degarelix for use in the treatment of prostate cancer in a subject identified as being at risk for cardiovascular disease. 
Pripravak koji sadrži degareliks za uporabu pri liječenju skeletnih metastaza ili metastaza kostiju, naznačen time da su skeletne metastaze ili metastaze kostiju posljedica karcinoma prostate.
A pharmaceutical composition as in claim 1 is used to treat traveler's diarrhea, hepatic encephalopathy, infectious diarrhea, diverticular disease, an antibacterial prophylactic prior to colon surgery, irritable bowel syndrome, Crohn's disease, Clostridum difficile-associated diarrhea, small intestinal bacterial overgrowth, traveler's diarrhea prophylaxis, dysentery, pouchitis, peptic ulcer disease, surgical prophylaxis and gastric dyspepsia. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da je za uporabu u liječenju putnih proljeva, hepatičke encefalopatije, zaraznih proljeva, divertikularne bolesti, za antibakterijsku profilaksu prije operacije debelog crijeva, za liječenje sindroma nadražljivih crijeva, Crohnove bolesti, proljeva uzrokovanog bakterijom Clostridium difficile, prekomjernog broja bakterija u tankom crijevu, za profilaksu putnog proljeva, za liječenje dizenterije, pouchitisa (upale kirurški oblikovane crijevne vrećice), za predoperativnu profilaksu 1 za liječenje želučane dispepsije.
A pharmaceutical composition that provides a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 
Farmaceutski pripravak koja sadrži spoj sukladno patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol.
Still furthermore, it is preferred according to the present invention that in case the following conditions are cumulatively verified, the first message is sent from the at least one specific remote node of the plurality of remote nodes: 
Metoda prema jednom od prethodnih zahtjeva, naznačena time da od više udaljenih čvorova (20) od najmanje jednog specifičnog udaljenog čvora (21) šalje se prva poruka u slučaju kumulativno provjerenih sljedećih uvjeta:
The method according to claim 20, wherein the ternesite clinker and a Portland cement clinker are ground together or separately, with or without sulfate carriers in the form of alkali and/or alkaline earth sulfates to degrees of fineness (according to Blaine) ranging from 2000 to 10000 cm2/g. 
Postupak sukladno zahtjevu 8, naznačen time što su ternesit klinker i portland cement klinker mljeveni zajedno ili odvojeno, sa ili bez nosača sulfata u obliku alkali i/ili alkalijskih zemnih sulfata, poželjno u obliku gipsa i/ili semihidrata i/ili anhidrata 1/ili magnezij sulfata, do stupnja finoće (sukladno Blaineu) opsega od 2000 do 10000 cm?/g, poželjno opsega od 3000 do 6000 cm?/g i poželjnije od 4000 do 5000 cm?/g.
The composition of claim 1, or the method of any one of claims 2 to 4, or the kit of claim 5 wherein said dsRNA duplex has a length of from 8 base pairs (bp) to 30 bp. 
navedeni dsRNA dupleks ima duljinu od 8 parova baza (bp) do 15 bp; navedeni dsRNA dupleks ima duljinu od 8 parova baza (bp) do 30 bp; ili
The compound or a pharmaceutically acceptable acid addition salt thereof according to [3], wherein R1 is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, an ethyl group, a 1,1-difluoroethyl group, a methoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, an ethoxy group, a 2-fluoroethoxy group, a 2-propyloxy group, a cyclopropylmethoxy group, a cyclopropyloxy group or an (oxetan-3-yl)oxy group. 
Spoj ili njegova farmaceutski prihvatljiva kisela adicijska sol prema zahtjevu 3, pri čemu R, je vodikov atom, fluorov atom, klorov atom, metilna skupina, fluorometilna skupina, difluorometilna skupina, trifluorometilna skupina, etilna skupina, 1,1-difluoroetilna skupina, metoksi skupina, fluorometoksi skupina, difluorometoksi skupina, trifluorometoksi skupina, etoksi skupina, 2-fluoroetoksi skupina, 2-propiloksi skupina, ciklopropilmetoksi skupina, ciklopropiloksi skupina ili (oksetan-3-il)oksi skupina.
A method of treating onychomycosis in a patient in need of such a treatment, which method comprises applying once weekly to the nails of said patient a composition consisting of: terbinafine and/or at least one pharmaceutically acceptable salt thereof in an amount of from 9 to 11% by weight of the composition, 
Pripravak koji se suštinski sastoji od: a) terbinafina i/ili najmanje njegove farmaceutski prihvatljive soli u količini od 9 do 11 % masenog udjela pripravka, b) hidroksipropil hitozan u količini od 0,1 do 0,6 % masenog udjela pripravka,
Process according to claim 1 or 2, wherein R1 and R2 independently represent C1 to C3 alkyl groups, advantageously methyl. 
Postupak prema zahtjevu 1 ili 2, naznačen time da R; i R, neovisno predstavljaju C1 do C3 alkil skupine, poželjno metil.
The compound according to [9] or a pharmacologically acceptable salt thereof, wherein in the formula (I), Ar1 is a group selected from the group consisting of B1), B2), B6b), B9c), and B9d): 
Spoj u skladu sa patentnim zahtjevom 9 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje 35 u formuli (1), Ar' je grupa odabrana iz grupe koja se sastoji od B1), B2), B6b), B9c), i B9d):
A pharmaceutical composition in unit dose form comprising multiparticulates according to any of claims 1 to 25, and multiparticulates of oxycodone antagonist. 
Uporaba multičestica prema bilo kojem od zahtjeva 1 do 13 u pripremi oblika koji ima analgetski učinak.
Each of the two RNA molecules of a subject two-molecule DNA-targeting RNA comprises a stretch of nucleotides that are complementary to one another such that the complementary nucleotides of the two RNA molecules hybridize to form the double stranded RNA duplex of the protein-binding segment. 
(ii) segment koji veže protein i koji međudjeluje s navedenim kimernim proteinom Cas9, pri čemu segment koji veže protein obuhvaća dva komplementarna odsjeka nukleotida koji hibridiziraju za tvorbu dvostruke RNK strukture (AdsRNK)-dupleks, gdje se navadeno stavljanje u doticaj provodi in vitro ili u stanici ex vivo.
The compounds according to the present invention are endowed with pronounced antipsychotic activity and possess a pharmacological profile characteristic of the atypical anti-psychotics, as demonstrated by the pharmacological assays carried out as described in WO 00/06579 and WO 02/10175, and therefore are useful for the preparation of a medicament for the treatment and prevention of acute and chronic psychotic disorders. 
Spojevi prema ovom izumu obdareni su s naglašenom antipsihotičnom aktivnošću te posjeduju farmakološki profil karakterističan za atipične antipsihotike, kao što je pokazano farmakološkim testovima koji su provedeni kao što je opisano u WO 00/06579 i WO 02/10175, te su stoga korisni za dobivanje lijekova za liječenje i prevenciju akutnih i kroničnih psihotičnih poremećaja.
The composition according to claim 1, wherein the cement is present at a ratio of 250-1700% of the mass of the expanded perlite. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da perlit sadrži najmanje 1% ukupne mase adhezivnog sastava.
Moreover, this tensioning device is further configured to allow the resting of the feet of the user, in a manner that said sliding movement can be done by the thrust of the legs. 
Isti mehanizam za napinjanje (7) konfiguriran je na način da korisniku omogućuje postavljanje stopala tako da on taj klizni pokret može aktivirati potiskivanjem stopala;
The assembly of claim 8, wherein the container (100) is provided with two opposing apertures (101) having a size and geometry corresponding to a nozzle (302) of the thruster (300). 
Montažni sklop prema zahtjevu 8, naznačen time, da je kontejner (100) opremljen s dva nasuprotna otvora (101) s veličinom i geometrijskim karakteristikama, koji odgovaraju mlaznici (302) propulzora (300).
Suitable halogen substituents in the compounds of the present invention include F, Cl, Br and I. 
Pogodni halogen supstituenti u spojevima predstavljenog izuma obuhvaćaju F, Cl, Bri I.
Floor panel according to claim 17, characterized in that the strip is snap-fitted in place in the recess (13). 
Podni panel prema patentnom zahtjevu 4 do 11, naznačen time što je umetak učvršćen umetanjem njegovog spojnog dijela (50) u udubljenje (13) napravljeno u tu svrhu.
Further, a high intensity sweetener is added in an amount sufficient to provide to the mixture a sweetness about equal to the sweetness of sugar. 
Nadalje, dodano je i sladilo u količini dovoljnoj da slatkoća smjese bude približno jednaka slatkoći šećera.
to R3 each independently represents a hydrogen atom, an unsubstituted or substituted C1-8 alkyl group, an unsubstituted or substituted C2-8 alkenyl group, an unsubstituted or substituted C2-8 alkynyl group, an unsubstituted or substituted C3-8 cycloalkyl group, an unsubstituted or substituted C4-8 cycloalkenyl group, an unsubstituted or substituted C6-10 aryl group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted C1-8 acyl group, an unsubstituted or substituted (1-imino)C1-8 alkyl group, an unsubstituted or substituted carboxyl group, an unsubstituted or substituted carbamoyl group, an unsubstituted or substituted hydroxyl group, an unsubstituted or substituted amino group, an unsubstituted or substituted mercapto group, a substituted sulfonyl group, a halogeno group, a cyano group, or a nitro group; 
do R3 svaki neovisno predstavlja vodikov atom, nesupstituiranu ili supstituiranu skupinu C1-8 alkil, nesupstituiranu ili supstituiranu skupinu C2-8 alkenil, nesupstituiranu ili supstituiranu skupinu C2-8 alkinil, nesupstituiranu ili supstituiranu skupinu C3-8 cikloalkil, nesupstituiranu ili supstituiranu skupinu C4-8 cikloalkenil, nesupstituiranu ili supstituiranu skupinu C6-10 aril, nesupstituiranu ili supstituiranu heterocikličku skupinu, nesupstituiranu ili supstituiranu skupinu C1-8 acil, nesupstituiranu ili supstituiranu skupinu (1-imino)C1-8 alkil, nesupstituiranu ili supstituiranu karboksilnu skupinu, nesupstituiranu ili supstituiranu karbamoil skupinu, nesupstituiranu ili supstituiranu hidroksilnu skupinu, nesupstituiranu ili supstituiranu amino skupinu, nesupstituiranu ili supstituiranu merkapto skupinu, supstituiranu sulfonil skupinu, halogenu skupinu, cijano skupinu, ili nitro skupinu;
An appliance according to claim 4, wherein said self-biased device comprises a torsion spring with two spring arms engaged with the door and the casing respectively. 
Uređaj u skladu s patentnim zahtjevom 4, naznačen time što navedena samopodesiva naprava sadrži torzijsku oprugu (136), gdje dva kraka opruge međudjeluju s vratima, odnosno s kućištem.
When the amine-protecting group is a catalytically removable amine-protecting group, it is conveniently deprotected by catalytic reduction or isomerization, though even such groups as benzyloxycarbonyl, generally considered catalytically removable, may also be removed acidolytically. 
Kada je amino- zaštitna skupina katalitički uklonjiva amino- zaštitna skupina, tada je prikladno deprotektiranje katalitičkom redukcijom ili izomerizacijom, premda takve skupine kao benziloksikarbonil, općenito su katalitički uklonjive, a mogu se ukloniti i acidokatalitički.
a piercer 11 held in slideable relation to a support wall, along the axis of the cylindrical support wall; and 
- - bušilo 11 koje se drži u kliznom odnosu prema nosećoj stijenci, uzduž osi cilindrične noseće stijenke; i
A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija, naznačena time, što sadrži spoj iz bilo kojeg od patentnih zahtjeva 1-5 i farmaceutski prihvatljivi nosač.
The forming method according to any of the claims from 10 to 12, characterised in that the step of forming a socket with the heated end (20) of the pipe (2) comprises the sub-steps of: 
Postupak oblikovanja prema zahtjevu 9 ili 10, naznačen time da korak formiranja čahure sa zagrijanim završetkom (20) cijevi (2) sadrži pod-korake:
The compound or mixture of compounds for use according to claim 8, wherein the compound or mixture of compounds and said other therapeutic agent are provided in combination. 
Spoj, ili smjesa spojeva, namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što se spoj, ili smjesu spojeva, i navedeno drugo terapijsko sredstvo osigurava u kombinaciji.